Study will generate a key reference data set
with Illumina Protein Prep solution
SAN
DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina,
Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and
array-based technologies, today announced a pilot proteomics
program to analyze 50,000 UK Biobank samples in collaboration with
deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson &
Johnson, and Novartis. The pilot program is based on Illumina's
upcoming proteomics assay, Illumina Protein Prep™, powered by
SOMAmer® technology, a next-generation sequencing (NGS) based
solution that will help scale access to proteomic insights.
Proteomics enables the observation of direct cellular function
to improve understanding of the role of proteins in health and
disease, and facilitates biomarker discovery for conditions such as
cancer and cardiovascular disease. Researchers use protein
quantitative trait loci (pQTLs), which are emerging as a vital
proteogenomic tool for drug discovery, linking genetic variation
with protein expression data and disease or other phenotypes. With
the advent of high-throughput proteomics methods such as Illumina
Protein Prep, the discovery of new pQTLs is now more
accessible.
"UK Biobank data has set the standard as a reference dataset for
the omics community, and we're excited to collaborate across the
health care industry in this pilot study as we prepare to launch
Illumina Protein Prep," said Steve
Barnard, PhD, chief technology officer of Illumina. "We
believe the pilot program will generate a new collection of
high-quality, NGS-based proteomics data for the research community
and pharma partners to advance biological insights."
UK Biobank will provide 50,000 samples from the same study
participants who are included in the UK Biobank Pharma
Proteomics Project, a separate research collaboration between the
UK Biobank and 14 biopharmaceutical companies. deCODE Genetics will
process the samples using the Illumina Protein Prep solution and
NovaSeq™ X Plus system, and run analysis using the
DRAGEN Protein Quantification pipeline. The first 30,000 samples
are funded through coinvestment from Illumina, deCODE Genetics, and
Standard BioTools, Inc., with automation partner support from
Tecan. The data generated from these first 30,000 samples will
be made available by UK Biobank immediately to the scientific
research community upon completion and when the resulting data has
undergone quality control, expected in the second half
2025.
For the data generated from an additional 20,000 samples, in
alignment with UK Biobank's standard practice, members of the
industry consortium will have a period of exclusive access.
Industry participants include deCODE Genetics and pharma
collaborators GSK, Johnson & Johnson, and Novartis. Following
that period, the data will be made available by UK Biobank to
the wider scientific research community. Illumina anticipates that
additional companies will join the consortium.
Professor Sir Rory Collins,
Principal Investigator and chief executive of UK Biobank said:
"This addition of increasingly rich proteomics data will help
researchers paint an even more dynamic picture of how an
individual's genetics, environment and lifestyle come together to
impact the development of different diseases."
"This project complements the work of the UK Biobank Pharma
Proteomics Project, by providing additional proteomic assay data
for 50,000 of the UK Biobank volunteers' blood samples. I am
excited to see how the global scientific community will use these
different sources of data to make leaps forward in the development
of new ways to prevent and treat a wide range of diseases."
"Proteomics is entering a transformative era, with the human
health impact constrained to date by the limits of legacy
technologies," said Michael Egholm,
PhD, chief executive officer of Standard BioTools Inc. "Today marks
a critical milestone, as we seamlessly integrate DNA-based
SOMAmers' unparalleled multiplexing capacity with the leading NGS
platform, and unlock the power of the UK Biobank to accelerate
human health."
The Illumina Protein Prep assay detects 9000 unique human
proteins powered by 11,000 SOMAmer (Slow Off-rate Modified
Aptamers) reagents, enabling sample-to-analysis proteomics
discovery studies. The solution has been in early access limited
release with customers, detecting 6000 human proteins, and is
compatible with the NovaSeq X, NovaSeq X Plus, and NovaSeq 6000
Systems, enabling multiomics on a single platform. The
solution will launch in the first half of 2025.
Use of forward-looking statements
This release may contain forward-looking statements that involve
risks and uncertainties. Among the important factors to which our
business is subject that could cause actual results to differ
materially from those in any forward-looking statements are: (i)
challenges inherent in developing and launching new products and
services, including modifying and scaling manufacturing operations,
and reliance on third-party suppliers for critical components; (ii)
our ability to manufacture robust instrumentation and consumables;
and (iii) the acceptance by customers of our newly launched
products, which may or may not meet our and their expectations,
together with other factors detailed in our filings with the
Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We undertake no obligation, and do not intend, to
update these forward-looking statements, to review or confirm
analysts' expectations, or to provide interim reports or updates on
the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as a global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit illumina.com and connect with us on X,
Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli
Schwartz
858-291-6421
IR@illumina.com
Media:
Christine
Douglass
PR@illumina.com
View original
content:https://www.prnewswire.com/news-releases/illumina-launches-pilot-proteomics-program-with-uk-biobank-and-biopharma-collaborators-to-analyze-50-000-samples-302348923.html
SOURCE Illumina, Inc.